Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
81.22(c) 80.44(c) 79.88(c) 80.92(c) 80.16 Last
2 155 345 974 258 802 735 872 653 163 780 Volume
-3.53% -0.96% -0.70% +1.30% -0.94% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 672 M - -
Net income 2021 -582 M - -
Net cash position 2021 354 M - -
P/E ratio 2021 -11,3x
Yield 2021 -
Sales 2022 841 M - -
Net income 2022 -510 M - -
Net Debt 2022 112 M - -
P/E ratio 2022 -13,8x
Yield 2022 -
Capitalization 7 035 M 7 035 M -
EV / Sales 2021 9,95x
EV / Sales 2022 8,50x
Nbr of Employees 866
Free-Float 95,6%
More Financials
Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular... 
More about the company
Ratings of Sarepta Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SAREPTA THERAPEUTICS, INC.
10/15SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quarter Ended..
PU
10/15SAREPTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operat..
AQ
10/15SAREPTA THERAPEUTICS : Credit Suisse Lowers Sarepta Therapeutics' PT to $95 from $100, Upd..
MT
10/15SAREPTA THERAPEUTICS : Berenberg Bank Boosts Price Target on Sarepta Therapeutics to $90 F..
MT
10/14SAREPTA THERAPEUTICS : Prices Public Offering at $81/Share, Expects $500 Million Gross Pro..
MT
10/13Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
GL
10/13SAREPTA THERAPEUTICS : Announces Pricing of $500 Million Public Offering of Common Stock
GL
10/13Health Care Stocks Edging Higher Ahead of Wednesday Close
MT
10/13SAREPTA THERAPEUTICS : Cash Levels Drop From Year-End 2020; Shares Down
MT
10/12SAREPTA THERAPEUTICS : Estimates Higher Q3 Product Revenue
MT
10/12SAREPTA THERAPEUTICS : Starts $500 Million Common Stock Offering
MT
10/12SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quar-ter Ende..
AQ
10/12SAREPTA THERAPEUTICS : Announces Proposed $500,000,000 Public Offering of Common Stock
AQ
10/12SAREPTA THERAPEUTICS : BTIG Adjusts Sarepta Therapeutics' Price Target to $125 from $110, ..
MT
10/12SAREPTA THERAPEUTICS : Credit Suisse Lifts Sarepta Therapeutics' PT to $100 from $75, Rais..
MT
More news
News in other languages on SAREPTA THERAPEUTICS, INC.
10/14Sarepta Therapeutics propose un appel public à l'épargne à 81 dollars par action et pré..
10/13Les actions du secteur de la santé en hausse avant la clôture de mercredi
10/13Les niveaux de trésorerie de Sarepta Therapeutics chutent par rapport à la fin de l'ann..
10/12Sarepta Therapeutics prévoit une hausse de ses revenus de produits au troisième trimest..
10/12Sarepta Therapeutics lance une offre d'actions ordinaires pour un montant de 500 millio..
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
More recommendations
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | SRPT | US8036071004 | MarketScreener
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 80,92 $
Average target price 120,05 $
Spread / Average Target 48,4%
EPS Revisions
Managers and Directors
Douglas S. Ingram President, Chief Executive Officer & Director
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
M. Kathleen Behrens Wilsey Chairman
Gilmore O’Neill Chief Medical Officer & Executive Vice President
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SAREPTA THERAPEUTICS, INC.-52.54%7 035
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536